Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             305 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 CE2: HANDLING MISSING DATA IN STOCHASTIC COST-EFFECTIVENESS ANALYSIS: THE IMPACT OF IMPUTATION METHODS ON ESTIMATES OF THE PHYSICAL QUANTITIES OF MEDICAL CARE RESOURCE USE Bell, T
 2001
 4 6 p. 405-
1 p.
 artikel
2 CE1: IMPACT OF CENSORED COST DATA ON THE OUTCOMES OF ECONOMIC EVALUATIONS Oostenbrink, JB
 2001
 4 6 p. 404-405
2 p.
 artikel
3 CE3: THE COST OF UPPER GASTRODUODENAL ENDOSCOPY: AN ACTIVITY-BASED APPROACH Crott, R
 2001
 4 6 p. 405-406
2 p.
 artikel
4 CH1: DEVELOPMENT OF A MINIMUM DATASET (MDS)-BASED COMORBIDITY INDEX FORA NURSING HOME POPULATION Gilsenan, A
 2001
 4 6 p. 417-418
2 p.
 artikel
5 CH2: TRANSITION IN HEALTH-RELATED QUALITY OF LIFE IN U.S. ELDERLY Zhang, JX
 2001
 4 6 p. 418-
1 p.
 artikel
6 CH3: TRENDS IN POPULATION-BASED HEALTH-RELATED QUALITY OF LIFE: IMPLICATIONS FOR INTERPRETATION OF CHANGE Erickson, P
 2001
 4 6 p. 418-419
2 p.
 artikel
7 CN3: AN ECONOMIC MODEL FOR THE PHARMACOLOGICAL MANAGEMENT OF ADVANCED NON-SMALL CELL LUNG CANCER IN THE US Sorensen, SV
 2001
 4 6 p. 403-
1 p.
 artikel
8 CN5: A SPECIFIC QUALITY OF LIFE SCALE IN UPPER LIMB LYMPHOEDEMA: THE ULL-27 QUESTIONNAIRE Launois, R
 2001
 4 6 p. 407-408
2 p.
 artikel
9 CN1: BRIEF ASSESSMENT OF PRIORITY SYMPTOMS IN HORMONE REFRACTORY PROSTATE CANCER (HRPCA) Yount, SE
 2001
 4 6 p. 402-
1 p.
 artikel
10 CN6: MEN'S PREFERENCES FOR THE CONSERVATIVE MANAGEMENT OF NON-METASTATIC PROSTATE CANCER: THE USE OF CONJOINT ANALYSIS Sculpher, M
 2001
 4 6 p. 408-
1 p.
 artikel
11 CN2: RESOURCE CONSUMPTION RELATED TO MUCOSITIS IN LYMPHOMA PATIENTS RECEIVING HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS PBPC TRANSPLANTATION Chan, WW
 2001
 4 6 p. 402-403
2 p.
 artikel
12 CN4: THE IMPACT OF THE DIAGNOSIS OF CANCER ON OUT-OF-POCKET HEALTH-CARE EXPENDITURES MADE BY THE US ELDERLY Langa, K
 2001
 4 6 p. 407-
1 p.
 artikel
13 CV2: A SIX YEAR FOLLOW-UP STUDY OF THE RELATIONSHIP BETWEEN MORTALITY, HOSPITALISATION AND ADHERENCE TO STATIN TREATMENT AFTER FIRST MYOCARDIAL INFARCTION Wei, L
 2001
 4 6 p. 404-
1 p.
 artikel
14 CV4: COMPARISON BETWEEN INVESTIGATOR AND PATIENT'S GLOBAL HEALTH ASSESSMENTS USING CALCULATED HUI-III AND SF-36 UTILITY VALUES Hatoum, HT
 2001
 4 6 p. 408-
1 p.
 artikel
15 CV1: ESTIMATING THE IMPACT OF ANTICOAGULATION QUALITY ON EVENT RATES Matchar, PB
 2001
 4 6 p. 403-404
2 p.
 artikel
16 CV6: EXCESS MORBIDITY AND COST OF FAILING TO ACHIEVE TARGETS FOR BLOOD PRESSURE CONTROL IN THE ELDERLY Lloyd, AC
 2001
 4 6 p. 409-
1 p.
 artikel
17 CV5: ORLISTAT IN OBESE TYPE 2 DIABETIC PATIENTS: ASSESSMENT OF LONG TERM OUTCOMES AND COST-EFFECTIVENESS Lamotte, M
 2001
 4 6 p. 408-409
2 p.
 artikel
18 CV3: VASOPEPTIDASE INHIBITOR REDUCES IN-HOSPITAL COSTS FOR CONGESTIVE HEART FAILURE PATIENTS: RESULTS FROM THE IMPRESS TRIAL Eisenstein, EL
 2001
 4 6 p. 404-
1 p.
 artikel
19 DB3: A DYNAMIC, THREE-PART MODEL FOR PREDICTING HOSPITAL COSTS IN TYPE 2 DIABETIC PATIENTS Wang, J
 2001
 4 6 p. 411-412
2 p.
 artikel
20 DB2: BOTTOM UP VERSUS TOP DOWN COST ESTIMATES FOR TYPE 2 DIABETES Koopmanschap, MA
 2001
 4 6 p. 411-
1 p.
 artikel
21 DB1: ESTIMATING HEALTH-CARE COSTS ASSOCIATED WITH DIABETES-RELATED COMPLICATIONS USING DATA FROM THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY (UKPDS) Gray, A
 2001
 4 6 p. 410-411
2 p.
 artikel
22 DS3: DESIGN AND ANALYSIS OF UNIT COST ESTIMATION STUDIES: HOW MANY TYPES OF HOSPITALIZATION? HOW MANY COUNTRIES? Glick, HA
 2001
 4 6 p. 410-
1 p.
 artikel
23 DS1: PATIENT-REPORTED OUTCOMES: A COMPARISON OF TWO DATA-CAPTURE METHODS Hufford, MR
 2001
 4 6 p. 409-410
2 p.
 artikel
24 DS2: POWER CALCULATIONS FOR WIDELY USED PATIENT-REPORTED OUTCOMES (PRO) MEASURES IN WOMEN'S HEALTH TRIALS Abetz, L
 2001
 4 6 p. 410-
1 p.
 artikel
25 HP4: PRICING OF PHARMACEUTICALS IN CANADA AND EUROPE: A COMPARATIVE ANALYSIS Palmer, WN
 2001
 4 6 p. 406-
1 p.
 artikel
26 HP3: REGIONAL VARIATION IN PRESCRIPTION USE IN THE UNITED STATES Motheral, BR
 2001
 4 6 p. 402-
1 p.
 artikel
27 HP6: THE IMPACT OF PIPELINE DRUGS ON UNITED STATES DRUG EXPENDITURE GROWTH TRENDS Mullins, CD
 2001
 4 6 p. 406-407
2 p.
 artikel
28 HP2: TRANSLATING EVIDENCE TO PRACTICE IN BREAST CANCER Bloom, BS
 2001
 4 6 p. 401-402
2 p.
 artikel
29 HP5: USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN IRELAND Heerey, A
 2001
 4 6 p. 406-
1 p.
 artikel
30 HP1: VALIDITY OF THE MINIMUM-DATA-SET-BASED QUALITY INDICATOR FOR DETERMINING THE PREVALENCE OF ANTIPSYCHOTIC MEDICATION USAGE AMONG LOW RISK NURSING HOME RESIDENTS: A STATEWIDE ASSESSMENT Monroe, DM
 2001
 4 6 p. 401-
1 p.
 artikel
31 IN1: ESTIMATING THE POTENTIAL HEALTH GAIN AND COST CONSEQUENCES OF INTRODUCING A PRE-SCHOOL DTPA PERTUSSIS BOOSTER INTO THE UK CHILD VACCINATION SCHEDULE Stevenson, M
 2001
 4 6 p. 412-
1 p.
 artikel
32 IN2: THE ECONOMIC BURDEN OF VIRAL RESPIRATORY INFECTION IN THE UNITED STATES Fendrick, AM
 2001
 4 6 p. 412-
1 p.
 artikel
33 IN3: THE OBSERVED COSTS AND HEALTH-CARE USE OF CHILDREN IN A RANDOMIZED CONTROLLED TRIAL OF PNEUMOCOCCAL CONJUGATE VACCINE Ray, GT
 2001
 4 6 p. 412-413
2 p.
 artikel
34 MH5: COST OF THE FIRST, SECOND AND SUBSEQUENT EPISODE OF DEPRESSION IN POLAND Kiejna, A
 2001
 4 6 p. 416-
1 p.
 artikel
35 MH2: EFFICACY OF NURSE TELEHEALTH CARE AND PEER SUPPORT IN AUGMENTING TREATMENT OF DEPRESSION IN PRIMARY CARE Hunkeler, EM
 2001
 4 6 p. 413-414
2 p.
 artikel
36 MH6: MODELLING THE COSTS OF ILLNESS AND THE COSTS OF RELAPSE IN THE MANAGEMENT OF SCHIZOPHRENIA IN THE UK Launois, R
 2001
 4 6 p. 416-
1 p.
 artikel
37 MH3: RECENT WEIGHT GAIN AND THE COST OF ACUTE SERVICE USE AMONG INDIVIDUALS WITH SCHIZOPHRENIA Weiden, PJ
 2001
 4 6 p. 414-
1 p.
 artikel
38 MH4: SLEEP DISORDERS AND HEALTH RELATED QUALITY OF LIFE—AN EPIDEMIOLOGICAL SURVEY Isacson, D
 2001
 4 6 p. 415-416
2 p.
 artikel
39 MH1: SOAP-51: A QUALITY OF LIFE SURVEY FOR COMMUNITY-RESIDING INDIVIDUALS WITH SCHIZOPHRENIA Barr, JT
 2001
 4 6 p. 413-
1 p.
 artikel
40 ND2: ASSESSING THE QUALITY OF LIFE IN PARKINSON'S DISEASE Spottke, AE
 2001
 4 6 p. 417-
1 p.
 artikel
41 ND3: COST-EFFECTIVENESS OF CABERGOLINE COMPARED TO LEVODOPA IN EARLY PARKINSON'S DISEASE IN SWEDEN Lindgren, P
 2001
 4 6 p. 417-
1 p.
 artikel
42 ND1: INDIRECT COSTS DUE TO BACK PAIN IN THE UNITED STATES Mychaskiw, MA
 2001
 4 6 p. 416-417
2 p.
 artikel
43 PAO7: AN ECONOMIC EVALUATION OF THE COST OF EDEMA AND SYSTOLIC BLOOD PRESSURE DESTABILIZATION IN COX-2-TREATED PATIENTS WITH OSTEOARTHRITIS AND HYPERTENSION Becker, R
 2001
 4 6 p. 485-
1 p.
 artikel
44 PAO5: COST ANALYSIS OF CELECOXIB AND CONVENTIONAL NSAIDS WITH OR WITHOUT GASTROPROTECTIVE AGENTS FOR TREATMENT OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS You, JH
 2001
 4 6 p. 484-
1 p.
 artikel
45 PAO6: COST-EFFECTIVENESS ANALYSIS OF USING CELECOXIB IN THE TREATMENT OF OSTEOARTHRITIS Soto, J
 2001
 4 6 p. 484-485
2 p.
 artikel
46 PAO3: COST OF CARE FOR MEMBERS WITH ARTHRITIS—A MANAGED CARE PERSPECTIVE Schaffer, M
 2001
 4 6 p. 483-
1 p.
 artikel
47 PAO12: DIRECT MEDICAL COST OF OSTEOPOROSIS IN THE UNITED STATES: PROJECTIONS FOR 2000–2025 King, AB
 2001
 4 6 p. 487-
1 p.
 artikel
48 PAO9: DISABILITY, RESOURCE UTILISATION, AND WORK ABSENCES ASSOCIATED WITH OSTEOARTHRITIS (OA) AND RHEUMATOID ARTHRITIS (RA): AN INTERNATIONAL DATABASE ANALYSIS Crawford, B
 2001
 4 6 p. 485-486
2 p.
 artikel
49 PAO11: ECONOMIC ANALYSIS OF THE GUIDELINES FOR THE MANAGEMENT OF CORTICOSTEROIDINDUCED OSTEOPOROSIS IN RESPIRATORY PATIENTS Moore, MR
 2001
 4 6 p. 486-487
2 p.
 artikel
50 PAO2: ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS Lovas, K
 2001
 4 6 p. 483-
1 p.
 artikel
51 PAO10: PSYCHOMETRIC VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) Trudeau, E
 2001
 4 6 p. 486-
1 p.
 artikel
52 PAO14: THE COST-EFFECTIVENESS OF CALCIUM AND VITAMIN D3 SUPPLEMENTATION FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN Willis, M
 2001
 4 6 p. 487-488
2 p.
 artikel
53 PAO4: THE COST-EFFECTIVENESS OF CELECOXIB COMPARED TO DICLOFENAC IN PATIENTS WITH RHEUMATOID ARTHRITIS IN POLAND Orlewska, E
 2001
 4 6 p. 483-484
2 p.
 artikel
54 PAO8: THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS Barbieri, M
 2001
 4 6 p. 485-
1 p.
 artikel
55 PAO1: THERAPEUTIC COMPARABILITY OF COX-2 INHIBITORS Richter, A
 2001
 4 6 p. 482-483
2 p.
 artikel
56 PAO13: UNITED STATES COMMUNITY PHARMACISTS' INTERVENTIONS WITH FEMALE PATIENTS REGARDING OSTEOPOROSIS Berardo, DH
 2001
 4 6 p. 487-
1 p.
 artikel
57 PCN1: BASELINE ANEMIA AND RISK OF POOR RESPONSE TO CHEMOTHERAPY IN INTERMEDIATE GRADE NON-HODGKIN'S LYMPHOMA(IGNHL) PATIENTS Lawless, G
 2001
 4 6 p. 431-
1 p.
 artikel
58 PCN14: CHEMOTHERAPY-INDUCED NEUROPATHY IN OVARIAN CANCER COST EFFECTIVENESS ANALYSIS Hay, JW
 2001
 4 6 p. 436-
1 p.
 artikel
59 PCN19: CHOICE OF OPTIMAL ANTI-EMETIC STRATEGIES IN CANCER THERAPY Hartmann, M
 2001
 4 6 p. 438-
1 p.
 artikel
60 PCN9: COST-EFFECTIVENESS OF IMAGE-GUIDED VERSUS BLIND INSERTION OF HICKMAN LINES IN ADULT CANCER PATIENTS BY NURSES Boland, A
 2001
 4 6 p. 434-
1 p.
 artikel
61 PCN11: COST-EFFECTIVENESS OF SENTINEL LYMPH NODE MAPPING AND ADJUVANT INTERFERON THERAPY FOR STAGE II MELANOMA Wilson, LS
 2001
 4 6 p. 435-
1 p.
 artikel
62 PCN4: COST-EFFECTIVENESS OF URATE OXIDASE IN PREVENTION AND TREATMENT OF SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES Moeremans, K
 2001
 4 6 p. 432-
1 p.
 artikel
63 PCN10: COST OF HOSPITALIZATION FOR THORACIC SURGERY IN PATIENTS WITH LUNG CANCER IN GREECE Leftakis, A
 2001
 4 6 p. 435-
1 p.
 artikel
64 PCN8: COST OF MANAGING SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES Annemans, LJ
 2001
 4 6 p. 434-
1 p.
 artikel
65 PCN7: COST OF THE POST-PBPC REINFUSION PERIOD IN HIGH DOSE TREATMENT OF NON-HODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM Van Kriekinge, G
 2001
 4 6 p. 433-434
2 p.
 artikel
66 PCN2: COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE Lilliu, H
 2001
 4 6 p. 431-432
2 p.
 artikel
67 PCN16: ELAPSED TIME TO DISCLOSURE OF BRCAI/2 GENETIC TESTING RESULTS AND PARTICIPANTS' DISTRESS: PRELIMINARY FINDINGS FROM A RESEARCH SETTING Dorval, M
 2001
 4 6 p. 437-
1 p.
 artikel
68 PCN5: FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER — COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN Marchetti, M
 2001
 4 6 p. 433-
1 p.
 artikel
69 PCN6: MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) Sharplin, P
 2001
 4 6 p. 433-
1 p.
 artikel
70 PCN13: PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN Rubio Terrés, C
 2001
 4 6 p. 436-
1 p.
 artikel
71 PCN17: PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS Collins, G
 2001
 4 6 p. 437-438
2 p.
 artikel
72 PCN15: QOL CHANGE OVER TIME POST-REINFUSION OF PBPC IN HIGH DOSE TREATMENT OF NON-HODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM USE Van Kriekinge, G
 2001
 4 6 p. 436-437
2 p.
 artikel
73 PCN18: QUALITY OF LIFE IN CANCER CLINICAL TRIALS — AN OVERVIEW OF APPROACHES WITHIN THE EORTC Bottomley, A
 2001
 4 6 p. 438-
1 p.
 artikel
74 PCN12: THE RELATIONSHIP OF AGE AND DURATION OF HORMONAL THERAPY USE AMONG PATIENTS DIAGNOSED WITH CANCER OF THE PROSTATE Stolshek, B
 2001
 4 6 p. 435-436
2 p.
 artikel
75 PCN3: USING LEVEL OF EVIDENCE CRITERIA IN THE EVALUATION OF PHARMACOECONOMIC RESULTS Becker, R
 2001
 4 6 p. 432-
1 p.
 artikel
76 PCV12: A COMPARISON OF HEALTH-CARE UTILIZATION AND COSTS OF PATIENTS WITH BRADYCARDIA ONLY AND BRADYCARDIA WITH ATRIAL TACHYARRHYTHMIAS IN THE US, UK AND GERMANY Sorensen, SV
 2001
 4 6 p. 492-493
2 p.
 artikel
77 PCV19: A COST-EFFECTIVENESS ANALYSIS OF THE USE OF CARVEDILOL COMPARED TO BISOPROLOL IN CHRONIC HEART FAILURE Squire, I
 2001
 4 6 p. 495-
1 p.
 artikel
78 PCV25: A COST STUDY OF COMMON PRACTICE TREATMENT FOR CRITICAL LIMB ISCHEMIA IN MOSCOW, RUSSIA Vorobiov, P
 2001
 4 6 p. 497-498
2 p.
 artikel
79 PCV31: A DECISION-ANALYSIS MODEL FOR ENHANCING MEDICATION ADHERENCE IN PATIENTS TAKING STATINS Peterson, AM
 2001
 4 6 p. 500-
1 p.
 artikel
80 PCV21: A HEALTH-ECONOMIC ANALYSIS OF THE USE OF AMLODIPINE IN PATIENTS UNDERGOING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY IN THE U.K Casciano, R
 2001
 4 6 p. 496-
1 p.
 artikel
81 PCV10: A PHARMACOECONOMIC ANALYSIS OF PATIENT OUTCOMES IN THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES) IN NORWAY AND CANADA Doyle, J
 2001
 4 6 p. 491-492
2 p.
 artikel
82 PCV30: A POPULATION-BASED EUROPEAN STUDY OF PERSISTENCE IN NEWLY DIAGNOSED HYPERTENSIVE PATIENTS Gabriel, S
 2001
 4 6 p. 499-500
2 p.
 artikel
83 PCV4: ASSESSING THE IMPACT OF HYPERLIPIDEMIA TREATMENT WITH PRAVASTATIN AND SIMVASTATIN IN A LARGE COUNTY INSTITUTION Walker, CL
 2001
 4 6 p. 489-
1 p.
 artikel
84 PCV6: AVAPROMISE: A RANDOMIZED CLINICAL TRIAL FOR INCREASING COMPLIANCE THROUGH BEHAVIORAL MODIFICATION IN ESSENTIAL HYPERTENSION Hamet, P
 2001
 4 6 p. 490-
1 p.
 artikel
85 PCV15: CHRONIC VENOUS INSUFFICENCY (CVI) IN POLAND—A COST OF ILLNESS STUDY Czech, M
 2001
 4 6 p. 493-494
2 p.
 artikel
86 PCV28: COST-CONSEQUENCES OF LOW-MOLECULARWEIGHT HEPARIN (LMWH) COMPARED WITH HEPARIN IN UNSTABLE CORONARY ARTERY DISEASE IN JAPAN Kamae, I
 2001
 4 6 p. 498-499
2 p.
 artikel
87 PCV27: COST-EFFECTIVENESS ANALYSIS OF A CHEST PAIN UNIT—A RE-STRUCTURED APPROACH IN RISK STRATIFICATION OF CHEST PAIN You, JH
 2001
 4 6 p. 498-
1 p.
 artikel
88 PCV2: COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION Vorobiov, P
 2001
 4 6 p. 488-
1 p.
 artikel
89 PCV16: COST-EFFECTIVENESS OF AMLODIPINE TREATMENT IN PATIENTS WITH CORONARY ARTERY DISEASE IN THE U.K Doyle, J
 2001
 4 6 p. 494-
1 p.
 artikel
90 PCV8: COST-EFFECTIVENESS OF CLOPIDOGREL COMPARED WITH TICLOPIDINE IN THROMBOSIS PREVENTION: DECISION ANALYSIS TAKING INTO ACCOUNT SIDE-EFFECTS Vorobiov, P
 2001
 4 6 p. 491-
1 p.
 artikel
91 PCV22: COST-EFFECTIVENESS OF ENOXAPARIN AS VENOUS THROMBOEMBOLISM PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS de Lissovoy, G
 2001
 4 6 p. 496-497
2 p.
 artikel
92 PCV18: COST EFFECTIVENESS OF ENOXAPARIN VS. UNFRACTIONATED HEPARIN FOR THE PROPHYLAXIS OF DVT AND SUBSEQUENT LONG-TERM COMPLICATIONS IN TOTAL HIP REPLACEMENT SURGERY IN THE UNITED KINGDOM Botteman, M
 2001
 4 6 p. 495-
1 p.
 artikel
93 PCV9: COST-EFFECTIVENESS OF EPTIFIBATIDE IN THE UK BASED ON PURSUIT TRIAL Brown, RE
 2001
 4 6 p. 491-
1 p.
 artikel
94 PCV20: COST-EFFECTIVENESS STUDY TO DETERMINE THE IMPACT OF A TOBACCO OUTREACH PROGRAM FOR ADOLESCENTS Lal, L
 2001
 4 6 p. 495-496
2 p.
 artikel
95 PCV14: COST-OF-ILLNESS STUDY OF UNSTABLE ANGINA PECTORIS IN GERMANY Smala, A
 2001
 4 6 p. 493-
1 p.
 artikel
96 PCV24: COSTS OF HYPERTENSION IN POLAND Hermanowski, T
 2001
 4 6 p. 497-
1 p.
 artikel
97 PCV32: DEVELOPMENT OF TWO INSTRUMENTS: ONE TO MEASURE EDUCATIONAL MATERIAL ACCEPTABILITY AND ONE TO MEASURE KNOWLEDGE GAINED IN PATIENTS WITH HEART FAILURE Gwadry-Sridhar, FH
 2001
 4 6 p. 500-501
2 p.
 artikel
98 PCV17: ECONOMIC EVALUATION OF ENOXAPARIN IN PATIENTS WITH ACUTE MEDICAL ILLNESS: AN ITALIAN ECONOMIC STUDY FROM THE MEDENOX TRIAL Nuijten, M
 2001
 4 6 p. 494-495
2 p.
 artikel
99 PCV13: EFFECT OF AMLODIPINE TREATMENT ON CARDIOVASCULAR DISEASE-RELATED HOSPITALIZATIONS AND COSTS IN PATIENTS WITH CORONARY ARTERY DISEASE IN SPAIN Galduf, J
 2001
 4 6 p. 493-
1 p.
 artikel
100 PCV7: ENOXAPARIN — A PHARMACOECONOMIC REVIEW OF ITS USE IN ACUTE CORONARY SYNDROMES Cal, ML
 2001
 4 6 p. 490-491
2 p.
 artikel
101 PCV3: ENOXAPARIN — A PHARMACOECONOMIC REVIEW OF ITS USE IN THROMBOEMBOLIC PROPHYLAXIS Cal, ML
 2001
 4 6 p. 489-
1 p.
 artikel
102 PCV26: HOW MUCH DOES ONE GRAM OF HUMAN HEART MUSCLE COST? Czech, M
 2001
 4 6 p. 498-
1 p.
 artikel
103 PCV33: IMPACT OF INSURANCE TYPES ON PATTERNS OF ANTIHYPERTENSIVE DRUG UTILIZATION: DIURETICS OR BETA-BLOCKERS VS. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS OR CALCIUM CHANNEL BLOCKERS Guo, D
 2001
 4 6 p. 501-
1 p.
 artikel
104 PCV5: IMPACT OF NON-COMPLIANCE ON THE COSTEFFECTIVENESS OF STATIN THERAPY Hughes, DA
 2001
 4 6 p. 489-490
2 p.
 artikel
105 PCV1: LONG-TERM COST-BENEFIT SIMULATION OF SIBUTRAMINE USING A MARKOV MODEL Evers, T
 2001
 4 6 p. 488-
1 p.
 artikel
106 PCV23: MODELLING THE COSTS OF ILLNESS IN THE MANAGEMENT OF CEREBROVASCULAR ACCIDENTS IN FRANCE Mègnigbêto, A
 2001
 4 6 p. 497-
1 p.
 artikel
107 PCV29: PERSISTENCY OF TREATMENT IN PATIENTS INITIATED ON FIVE DIFFERENT CLASSES OF ANTIHYPERTENSIVE THERAPY: A PHARMACO-UTILIZATION AND PHARMACO-ECONOMIC ANALYSIS Valpiani, G
 2001
 4 6 p. 499-
1 p.
 artikel
108 PCV35: STOP SMOKING CESSATION TARGET: OBSERVATION PROGRAM AN EX-SMOKER IS A SMOKER IN PROGRESSION Lagrue, G
 2001
 4 6 p. 501-502
2 p.
 artikel
109 PCV34: STOP SMOKING CESSATION TARGET: OBSERVATION PROGRAM, THE FRENCH PHARMACIST'S PROGRESS Rouzaud, P
 2001
 4 6 p. 501-
1 p.
 artikel
110 PCV11: THE COST-EFFECTIVENESS OF LEVOSIMENDAN IN SEVERE LOW-OUTPUT HEART FAILURE COMPARED TO DOBUTAMINE BASED ON AN INTERNATIONAL CLINICAL TRIAL (LIDO) Cleland, J
 2001
 4 6 p. 492-
1 p.
 artikel
111 PDG14: AN ASSESSMENT OF THE COSTEFFECTIVENESS OF PIOGLITAZONE (ACTOS*NF, TAKEDA) IN TYPE 2 DIABETES MELLITUS IN DENMARK Jansen, R
 2001
 4 6 p. 507-508
2 p.
 artikel
112 PDG17: AN ECONOMIC ANALYSIS OF IRBESARTAN IN TYPE II DIABETIC NEPHROPATHY Rodby, R
 2001
 4 6 p. 508-509
2 p.
 artikel
113 PDG3: AN ECONOMIC EVALUATION OF COMBINATION THERAPY WITH PIOGLITAZONE (ACTOS, TAKEDA) IN TYPE 2 DIABETES MELLITUS FROM A SPANISH HEALTH-CARE PERSPECTIVE Maniadakis, N
 2001
 4 6 p. 503-
1 p.
 artikel
114 PDG10: A PHARMACOECONOMIC MODEL OF HbA1c CONTROL IN THE TREATMENT OF TYPE 2 DIABETES Lilliu, H
 2001
 4 6 p. 506-
1 p.
 artikel
115 PDG8: A POPULATION STUDY OF HEALTH-CARE COSTS ASSOCIATED WITH HYPOGLYCAEMIA Wang, J
 2001
 4 6 p. 505-
1 p.
 artikel
116 PDG20: A SIMULATION MODEL TO CALCULATE LONGTERM COSTS AND LIFE EXPECTANCY DEPENDENT ON POST PRANDIAL BLOOD GLUCOSE LEVELS IN DIABETES PATIENTS Palmer, AJ
 2001
 4 6 p. 510-
1 p.
 artikel
117 PDG13: ASSESSING PATIENT CARE AND COST OF PATIENTS WITH TYPE 2 DIABETES IN GERMANY—AN ANALYSIS ACROSS DIFFERENT TREATMENT TYPES Goertz, A
 2001
 4 6 p. 507-
1 p.
 artikel
118 PDG16: BUDGETARY IMPACT OF TREATMENT GUIDELINES—THE EXAMPLE OF TYPE 2 DIABETES Pirk, O
 2001
 4 6 p. 508-
1 p.
 artikel
119 PDG12: CLINICAL BENEFITS AND COST-OFFSETS OF COMBINATION THERAPY WITH NATEGLINIDE PLUS METFORMIN VERSUS METFORMIN ALONE IN DIABETES IN THE NETHERLANDS van den, Boom G
 2001
 4 6 p. 506-507
2 p.
 artikel
120 PDG6: COST-EFFECTIVENESS OF PIOGLITAZONE (ACTOS®, TAKEDA) IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN Henriksson, F
 2001
 4 6 p. 504-
1 p.
 artikel
121 PDG25: ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD Beard, S
 2001
 4 6 p. 511-512
2 p.
 artikel
122 PDG22: EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES: A PILOT STUDY Wee, HL
 2001
 4 6 p. 510-511
2 p.
 artikel
123 PDG11: HEALTH AND ECONOMIC OUTCOMES OF A NEW ORAL DIABETES DRUG, PIOGLITAZONE (ACTOS*NF, TAKEDA), IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN NORWAY Brandt, A
 2001
 4 6 p. 506-
1 p.
 artikel
124 PDG27: HEALTH STATE UTILITIES IN GERD PATIENTS WITH HEARTBURN A STUDY IN GERMANY AND SWEDEN Kartman, B
 2001
 4 6 p. 512-513
2 p.
 artikel
125 PDG21: HUMANISTIC IMPACT OF HYPERGLYCEMIA IN TYPE 1 DIABETES MELLITUS Summers, KH
 2001
 4 6 p. 510-
1 p.
 artikel
126 PDG5: MODELING THE IMPACT OF A NEW ORAL ANTI-DIABETIC TREATMENT ON DIABETES COMPLICATION COSTS IN FRANCE Brun-Strang, C
 2001
 4 6 p. 504-
1 p.
 artikel
127 PDG23: PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT: THE EFFECTS OF THE INTRODUCTION OF A DISEASE MANAGEMENT GUIDELINE Degli, Esposti L
 2001
 4 6 p. 511-
1 p.
 artikel
128 PDG24: PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA Snegova, E
 2001
 4 6 p. 511-
1 p.
 artikel
129 PDG2: RISK OF DIABETES AMONG RISPERIDONE AND OLANZAPINE USERS Moisan, J
 2001
 4 6 p. 502-503
2 p.
 artikel
130 PDG15: THE COST OF TREATING DIABETIC FOOT ULCERS (DFU) WITH APLIGRAF IN THE NETHERLANDS McDonnell, J
 2001
 4 6 p. 508-
1 p.
 artikel
131 PDG4: THE DIFFERENTIAL EFFECT OF SULPHONYLUREA OR BIGUANIDE DRUGS ON CARDIAC REVASCULARIZATION PROCEDURES IN DIABETICS Shilo, L
 2001
 4 6 p. 503-
1 p.
 artikel
132 PDG9: THE EVENT AND STATE COST OF COMPLICATIONS OF DIABETES IN THE NETHERLANDS Koopmanschap, MA
 2001
 4 6 p. 505-506
2 p.
 artikel
133 PDG26: THE IMPACT OF THE USE OF NEXIUM ON THE OVERALL PPI BUDGET IN GREECE Christodoulopoulou, A
 2001
 4 6 p. 512-
1 p.
 artikel
134 PDG7: THE LIFETIME DIRECT MEDICAL COSTS OF MANAGING DIABETES AND ITS COMPLICATIONS IN FRANCE Grueger, J
 2001
 4 6 p. 504-505
2 p.
 artikel
135 PDG1: THE OUTCOMES OF LONG-TERM TREATMENT OF A NEW ORAL DIABETES DRUG PIOGLITAZONE (ACTOS **) IN THE MANAGEMENT OF TYPE 2 DIABETES IN FINLAND Maniadakis, N
 2001
 4 6 p. 502-
1 p.
 artikel
136 PDG18: TREATMENT CHANGE FOLLOWING HEMOGLOBIN A1c TEST RESULTS AMONG DIABETIC PATIENTS Schabert, V
 2001
 4 6 p. 509-
1 p.
 artikel
137 PDG19: TRENDS IN USE OF ANTIDIABETICS IN THE CZECH REPUBLIC Sechser, T
 2001
 4 6 p. 509-510
2 p.
 artikel
138 PEE5: COSTS AND CONSEQUENCES OF LASIK, GLASSES AND CONTACT LENSES IN MILD TO MODERATE MYOPIA—A SPANISH SOCIETAL APPROACH Alio y Sanz, J
 2001
 4 6 p. 514-515
2 p.
 artikel
139 PEE3: COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS CROMOLYN SODIUM 2% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS Lafuma, A
 2001
 4 6 p. 514-
1 p.
 artikel
140 PEE2: COSTS AND CONSEQUENCES OF OLOPATADINE 0.1% VERSUS LEVOCABASTINE 0.05% IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS Lafuma, A
 2001
 4 6 p. 513-
1 p.
 artikel
141 PEE10: IS NON-CONTACT NORMOTHERMIC WOUND THERAPY COST-EFFECTIVE FOR THE TREATMENT OF STAGE 3 AND 4 PRESSURE ULCERS? Macario, A
 2001
 4 6 p. 516-517
2 p.
 artikel
142 PEE1: LONG TERM CLINICAL CONSEQUENCES OF ND:YAG LASER CAPSULOTOMY FOLLOWING POSTERIOR CAPSULAR OPACIFICATION AFTER CATARACT SURGERY — A MARKOV MODEL APPROACH Billotte, C
 2001
 4 6 p. 513-
1 p.
 artikel
143 PEE6: PROSTAMIDES VS. COMBINATION PRODUCTS FOR GLAUCOMA TREATMENT: EFFECTIVENESS AND COST CONSIDERATIONS Evans, S
 2001
 4 6 p. 515-
1 p.
 artikel
144 PEE11: PSORIASIS AND EVERYDAY LIFE: FIRST RESULTS Corvest, M
 2001
 4 6 p. 517-
1 p.
 artikel
145 PEE8: QUALITY OF LIFE OF FRENCH PATIENTS TREATED FOR PRIMARY OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION Auzanneau, N
 2001
 4 6 p. 516-
1 p.
 artikel
146 PEE7: THE BURDEN OF AGE-RELATED MACULAR DEGENERATION—RESULTS OF A COHORT STUDY IN TWO FRENCH REFERRAL CARE CENTERS Bonastre, J
 2001
 4 6 p. 515-
1 p.
 artikel
147 PEE9: THE SOCIETAL COST OF ATOPIC DERMATITIS IN GERMANY Banz, K
 2001
 4 6 p. 516-
1 p.
 artikel
148 PEE12: THE WILLINGNESS TO PAY FOR PHARMACOTHERAPY OF ATOPIC DERMATITIS Ikeda, S
 2001
 4 6 p. 517-
1 p.
 artikel
149 PEE4: WELFARE COSTS OF VISUAL IMPAIRMENT Remak, E
 2001
 4 6 p. 514-
1 p.
 artikel
150 PHP17: A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC de Charro, FT
 2001
 4 6 p. 478-
1 p.
 artikel
151 PHP12: BARRIERS THAT PREVENT THE USE OF ECONOMIC EVALUATIONS IN HOSPITAL FORMULARY DECISION-MAKING Späth, HM
 2001
 4 6 p. 476-
1 p.
 artikel
152 PHP21: COST-BENEFIT ANALYSIS OF PREVENTING PRESCRIBING ERRORS BY HOSPITAL PHARMACISTS Van den Bemt, P
 2001
 4 6 p. 480-
1 p.
 artikel
153 PHP19: COST OF BLOOD PRODUCTS IN GERMAN HOSPITALS Spannheimer, A
 2001
 4 6 p. 479-
1 p.
 artikel
154 PHP24: CRITERIA FOR ASSESSING INTENSIVE CARE UNIT ADMISSIONS FROM THE EMERGENCY ROOM Gwadry-Sridhar, FH
 2001
 4 6 p. 481-
1 p.
 artikel
155 PHP2: GASTROINTESTINAL DRUG POLICY, DRUG SELECTION AND RESOURCE UTILIZATION—A COMPARISON OF THE CANADIAN PROVINCES OF QUEBEC AND ONTARIO Bell, NR
 2001
 4 6 p. 472-
1 p.
 artikel
156 PHP23: HOSPITAL READMISSIONS OF OLDER PEOPLE Abdelhafiz, AH
 2001
 4 6 p. 480-481
2 p.
 artikel
157 PHP16: HOW RESPONSIVE ARE OUR HEALTH CENTRES? Ferreira, PL
 2001
 4 6 p. 478-
1 p.
 artikel
158 PHP15: IMPACT OF FIRST GENERIC ENTRANTS ON BRAND NAME PRODUCTS Kleinstiver, P
 2001
 4 6 p. 477-478
2 p.
 artikel
159 PHP6: INSURANCE CLAIMS AS A DEVICE FOR MEASURING THE PHARMACISTS SUBSTITUTION RIGHT IN A FRENCH DEPARTMENT Mégnigbêto, A
 2001
 4 6 p. 474-
1 p.
 artikel
160 PHP1: INTEGRATING HEALTH ECONOMICS INTO THE PRODUCT DECISION- MAKING PROCESS: LESSONS LEARNED FROM DECISION-MAKERS Gevirtz, FO
 2001
 4 6 p. 472-
1 p.
 artikel
161 PHP3: MACRO-ECONOMIC ANALYSIS OF HEROIN MARKETS IN THE EU AND THE IMPACT OF SUBSTITUTION TREATMENT Annemans, LJ
 2001
 4 6 p. 472-473
2 p.
 artikel
162 PHP22: PERCEIVED QUALITY OF LIFE AND MEDICINE CONSUMPTION IN ELDERLY OUTPATIENTS Goicoechea, A
 2001
 4 6 p. 480-
1 p.
 artikel
163 PHP13: PHARMACOECONOMICS OF BLOOD TRANSFUSION SAFETY MEASURES: A REVIEW OF THE LITERATURE Postma, M
 2001
 4 6 p. 476-477
2 p.
 artikel
164 PHP7: PILOT STUDY TO DETERMINE THE DEMOGRAPHICS, REASONS, AND TYPES OF MEDICATIONS PURCHASED IN MEXICO BY US RESIDENTS Calvillo, JP
 2001
 4 6 p. 474-
1 p.
 artikel
165 PHP11: REVIEW AND ANALYSIS OF DIFFERENT METHODOLOGIES FOR THE CALCULATION AND DISTRIBUTION OF PRIMARY HEALTH CARE PHARMACEUTICAL BUDGETS IN EUROPE Gilabert, A
 2001
 4 6 p. 476-
1 p.
 artikel
166 PHP18: THE CLINICAL PHARMACIST AS A MEMBER OF THE MEDICAL WARD TEAM—A PILOT STUDY Shilo, L
 2001
 4 6 p. 478-479
2 p.
 artikel
167 PHP14: THE CURRENT STATUS AND FUTURE PROSPECTS FOR PHARMACOECONOMICS IN GREECE Karokis, A
 2001
 4 6 p. 477-
1 p.
 artikel
168 PHP20: THE ECONOMIC BURDEN OF PHYSICAL INACTIVITY IN SWITZERLAND Smala, AM
 2001
 4 6 p. 479-480
2 p.
 artikel
169 PHP9: THE INFLUENCE OF UPDATING THE ISRAELI NATIONAL DRUG LIST ON AVERAGE NUMBER OF DRUGS PRESCRIBED TO A PATIENT Klang, S
 2001
 4 6 p. 475-
1 p.
 artikel
170 PHP26: THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE Dickson, AJ
 2001
 4 6 p. 482-
1 p.
 artikel
171 PHP27: THE RELATIONSHIP BETWEEN NATIONAL HEALTH INSURANCE EXPENDITURE AND THE BURDEN OF DISEASE- AN EVIDENCE-BASED STUDY IN TAIWAN Liang, LY
 2001
 4 6 p. 482-
1 p.
 artikel
172 PHP10: THE ROAD TO JAPAN/KOREA 2002: PROSPECTS FOR JAPANESE PHARMACOECONOMICS Pang, F
 2001
 4 6 p. 475-
1 p.
 artikel
173 PHP25: THE USE OF ATC/DDD METHODOLOGY FOR REVIEWING COST OF DRUG EXPOSURE AT THE NATIONAL LEVEL Borissov, BN
 2001
 4 6 p. 481-
1 p.
 artikel
174 PHP8: THE USE OF ECONOMIC INFORMATION IN HOSPITAL FORMULARY DEVELOPMENT IN A FRENCH REGION Späth, HM
 2001
 4 6 p. 474-475
2 p.
 artikel
175 PHP5: USING PRESCRIBING DATA TO ESTIMATE PREVALENCE OF CHRONIC ILLNESS IN THE REPUBLIC OF IRELAND McElroy, B
 2001
 4 6 p. 473-
1 p.
 artikel
176 PHP4: WHAT IS A VALID PRESCRIBING INDICATOR? Gill, D
 2001
 4 6 p. 473-
1 p.
 artikel
177 PIN8: A COST-BENEFIT ANALYSIS OF INFLUENZA VACCINATION IN A COMPANY IN ITALY (ENI SPA) Colombo, GL
 2001
 4 6 p. 441-
1 p.
 artikel
178 PIN11: A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C Simons, WR
 2001
 4 6 p. 442-443
2 p.
 artikel
179 PIN21: ANTIBIOTIC PROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY: ASSESSMENT OF GLOBAL CONFORMITY TO FRENCH GUIDELINES Bedouch, P
 2001
 4 6 p. 446-447
2 p.
 artikel
180 PIN4: A RETROSPECTIVE ANALYSIS OF TREATMENT PATTERNS AND COSTS IN EXTERNAL GENITAL WARTS FOR THE NETHERLANDS van der Meijden, W
 2001
 4 6 p. 440-
1 p.
 artikel
181 PIN14: A STUDY ON THE HEALTH EFFECTS OF FLU AND FLU-LIKE ILLNESSES IN THE WORKING POPULATION AND THEIR COST IMPACT ON A BIG CORPORATION IN HONG KONG Lee, KK
 2001
 4 6 p. 443-444
2 p.
 artikel
182 PIN12: BURDEN OF ILLNESS IMPOSED BY SEVERE SEPSIS IN GERMANY Schmid, A
 2001
 4 6 p. 443-
1 p.
 artikel
183 PIN13: CAN VARICELLA BE ELIMINATED BY UNIVERSAL CHILDHOOD VACCINATION COST-BENEFICIALLY? EXAMPLES FOR EUROPE Goertz, A
 2001
 4 6 p. 443-
1 p.
 artikel
184 PIN9: COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS Jansema, P
 2001
 4 6 p. 441-442
2 p.
 artikel
185 PIN2: COST-EFFECTIVENESS OF HIV-SCREENING OF PATIENTS ATTENDING A CLINIC FOR SEXUALLY TRANSMITTED DISEASES IN AMSTERDAM Bos, J
 2001
 4 6 p. 439-
1 p.
 artikel
186 PIN16: COST-EFFECTIVENESS OF TERBINAFINE AND ITRACONAZOLE IN TOENAIL ONYCHOMYCOSIS IN POLAND: MODELLING STUDY WITH THREE-YEAR TIME HORIZON Orlewska, E
 2001
 4 6 p. 444-445
2 p.
 artikel
187 PIN5: COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS Welte, R
 2001
 4 6 p. 440-
1 p.
 artikel
188 PIN10: DEVELOPMENT AND VALIDATION OF A 17-COUNTRY EUROPEAN PHARMACOECONOMIC MODEL: THE ONYCHOTREE STUDY Baron, F
 2001
 4 6 p. 442-
1 p.
 artikel
189 PIN18: DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS Birnbaum, HG
 2001
 4 6 p. 445-
1 p.
 artikel
190 PIN15: ECONOMIC COMPARISON OF SEQUENTIAL (IV TO PO) CIPROFLOXACIN/METRONIDAZOLE VS PIPERACILLIN/TAZOBACTAM FOR THE TREATMENT OF PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS Gilliland, KK
 2001
 4 6 p. 444-
1 p.
 artikel
191 PIN6: ESTIMATED COSTS TO CONDUCT A PHASE III CLINICAL TRIAL OF A NEW PULMONARY TUBERCULOSIS DRUG Dombeck, M
 2001
 4 6 p. 440-441
2 p.
 artikel
192 PIN20: ESTIMATING THE RETURN ON INVESTMENT FOR TUBERCULOSIS DRUGS Mauskopf, JA
 2001
 4 6 p. 446-
1 p.
 artikel
193 PIN17: HOW CAN PRODUCTS WITH MARGINAL EFFICACY SAVE MONEY? THE EXAMPLE OF A NON SPECIFIC, IMMUNOSTIMULATING, PREVENTIVE TREATMENT FOR RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN Mégas, F
 2001
 4 6 p. 445-
1 p.
 artikel
194 PIN1: IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS' DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY Gyldmark, M
 2001
 4 6 p. 438-439
2 p.
 artikel
195 PIN7: PHARMACOECONOMIC EVALUATION OF IMIQUIMOD (ALDARA) FOR THE TREATMENT OF EXTERNAL GENITAL WARTS IN A DUTCH TREATMENT ENVIRONMENT Langley, P
 2001
 4 6 p. 441-
1 p.
 artikel
196 PIN19: POTENTIAL USE OF FLUOROQUINOLONES IN THE TREATMENT OF PULMONARY TUBERCULOSIS Dombeck, M
 2001
 4 6 p. 445-446
2 p.
 artikel
197 PIN22: PROPHYLAXIS AGAINST RSV, VARICELLA AND PNEUMOCOCCAL INFECTIONS: ECONOMIC-BASED DECISION-MAKING Strutton, DR
 2001
 4 6 p. 447-
1 p.
 artikel
198 PIN24: THE DEVELOPMENT AND VALIDATION OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE (IDDQ) Wild, DJ
 2001
 4 6 p. 447-448
2 p.
 artikel
199 PIN23: THE FIRST STEP TO GENERATING UTILITY FROM QUALITY OF LIFE: A COMPARISON OF ITEM PREFERENCES AND ITEM SEVERITY Doward, LC
 2001
 4 6 p. 447-
1 p.
 artikel
200 PIN3: THE IMPACT OF DRUG COMPLIANCE ON THE COST OF TREATING HIV/AIDS IN AFRICA Becker, R
 2001
 4 6 p. 439-440
2 p.
 artikel
201 PKU2: AN ECONOMIC MODEL OF UNSTABLE BLADDER IN ITALY Annoni, G
 2001
 4 6 p. 448-449
2 p.
 artikel
202 PKU1: COST-EFFECTIVENESS ANALYSIS OF THREE SURGICAL TREATMENTS FOR FEMALE STRESS URINARY INCONTINENCE Gao, X
 2001
 4 6 p. 448-
1 p.
 artikel
203 PKU4: COST-MINIMISATION STUDY COMPARING SIMULECT VERSUS THYMOGLOBULINE IN RENAL TRANSPLANT INDUCTION Lilliu, H
 2001
 4 6 p. 449-
1 p.
 artikel
204 PKU3: CUMULATIVE INCIDENCE AND TOTAL COSTS ASSOCIATED WITH URINARY AND OVERACTIVE BLADDER DISORDERS IN EMPLOYED POPULATIONS Muchmore, L
 2001
 4 6 p. 449-
1 p.
 artikel
205 PKU5: HEALTH-RELATED CONSEQUENCES AND COSTS OF OVERACTIVE BLADDER Wagner, T
 2001
 4 6 p. 449-450
2 p.
 artikel
206 PKU6: INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE®) IN SIX EUROPEAN COUNTRIES Arnould, B
 2001
 4 6 p. 450-
1 p.
 artikel
207 PMH14: ANTIPSYCHOTIC COMPLIANCE EVALUATION — A POPULATION-BASED, MANAGED-CARE STUDY OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC MEDICATION Simons, WR
 2001
 4 6 p. 456-
1 p.
 artikel
208 PMH16: ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: ADVERSE EVENTS, NON-COMPLIANCE AND COST Meddis, D
 2001
 4 6 p. 457-
1 p.
 artikel
209 PMH7: CHANGES IN SCHIZOPHRENIA-RELATED TOTAL DIRECT MEDICAL COSTS FOLLOWING INITIATION OF OLANZAPINE OR RISPERIDONE IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES Russo, P
 2001
 4 6 p. 453-
1 p.
 artikel
210 PMH21: CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH OLANZAPINE IN PATIENTS WITH BIPOLAR DISORDER AS COMPARED WITH HALOPERIDOL Shi, L
 2001
 4 6 p. 459-
1 p.
 artikel
211 PMH20: COMPARISON OF ADVERSE DRUG EVENTS (ADE) ASSOCIATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRI) IN TWO MANAGED CARE ORGANIZATIONS (MCO) Rascati, KL
 2001
 4 6 p. 458-
1 p.
 artikel
212 PMH18: DEPRESSION AND QUALITY OF LIFE AND THEIR EFFECT ON HEALTH-CARE UTILIZATION Bushnell, DM
 2001
 4 6 p. 457-458
2 p.
 artikel
213 PMH4: DRUG SELECTION, DOSING, AND UTILIZATION PATTERNS AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN US MANAGED CARE PLANS Valuck, RJ
 2001
 4 6 p. 452-
1 p.
 artikel
214 PMH9: ECONOMIC ANALYSIS OF PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER Swensen, A
 2001
 4 6 p. 454-
1 p.
 artikel
215 PMH24: HEALTH-CARE RESOURCE USE AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA White, RE
 2001
 4 6 p. 460-
1 p.
 artikel
216 PMH19: IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS Corey-Lisle, P
 2001
 4 6 p. 458-
1 p.
 artikel
217 PMH2: IMPROVEMENT IN QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC PATIENTS IS ASSOCIATED WITH ROBUST ACUTE TREATMENT RESPONSE OF OLANZAPINE VERSUS HALOPERIDOL Kinon, BJ
 2001
 4 6 p. 451-
1 p.
 artikel
218 PMH17: LONG-TERM ECONOMIC BENEFITS OF ANTIPSYCHOTIC USE Boscoe, AN
 2001
 4 6 p. 457-
1 p.
 artikel
219 PMH10: MANAGEMENT AND COST OF A MANIC EPISODE IN BIPOLAR DISORDER—A FRENCH STUDY Levy, E
 2001
 4 6 p. 454-
1 p.
 artikel
220 PMH25: MENTAL WELL-BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA Travers, J
 2001
 4 6 p. 460-
1 p.
 artikel
221 PMH3: PATIENT MEDICATION ATTITUDE AFTER SWITCHING TOZIPRASIDONE FROM OTHER ANTIPSYCHOTICS Dugar, A
 2001
 4 6 p. 451-452
2 p.
 artikel
222 PMH6: PATTERNS OF COMORBIDITIES AND COPRESCRIBING AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN US MANAGED CARE PLANS Valuck, RJ
 2001
 4 6 p. 452-453
2 p.
 artikel
223 PMH11: RETROSPECTIVE ECONOMIC EVALUATION OF MIRTAZAPINE, VENLAFAXINE XR AND SERTRALINE IN A MANAGED CARE POPULATION Pinto, LA
 2001
 4 6 p. 455-
1 p.
 artikel
224 PMH1: RIGOROUS CRITERIA FOR TREATMENT RESPONSE DIFFERENTIATED EFFICACY OF OLANZAPINE VERSUS HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA Kinon, BJ
 2001
 4 6 p. 450-451
2 p.
 artikel
225 PMH8: SCHIZOPHRENIA OUTCOMES RESEARCH STUDY IN SPAIN: TOLERABILITY AND ECONOMIC RESULTS WITH ATYPICAL ANTIPSYCHOTICS Rejas, J
 2001
 4 6 p. 453-454
2 p.
 artikel
226 PMH5: THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS—AN ECONOMIC ANALYSIS OF THE PRIZE STUDY Tilden, D
 2001
 4 6 p. 452-
1 p.
 artikel
227 PMH12: THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA (CNOMSS) Trakas, K
 2001
 4 6 p. 455-
1 p.
 artikel
228 PMH13: THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY FOR CHRONIC SCHIZOPHRENIA IN POLAND Niewada, MP
 2001
 4 6 p. 455-456
2 p.
 artikel
229 PMH15: THE IMPACT OF ALCOHOL ABUSE ON EMPLOYMENT IN SWITZERLAND Chevrou-Severac, H
 2001
 4 6 p. 456-
1 p.
 artikel
230 PMH23: THE USE OF NEFAZODONE IN THE TREATMENT OF POST TRAUMATIC STRESS DISORDER Voris, JC
 2001
 4 6 p. 459-460
2 p.
 artikel
231 PMI13: A COMPARISON OF EQ-5D TIME TRADE-OFF VALUES OBTAINED IN GERMANY, UK AND SPAIN: COULD THERE BE ONE EUROPEAN EQ TARIFF? Busschbach, JJ
 2001
 4 6 p. 425-426
2 p.
 artikel
232 PMI5: A PROBLEM WITH STOCHASTIC ECONOMIC EVALUATION WHEN THE TIME HORIZONS FOR THE COST AND EFFECTIVENESS MEASUREMENTS ARE ASYMMETRICAL Backhouse, M
 2001
 4 6 p. 422-423
2 p.
 artikel
233 PMI20: A REAL OPTION APPROACH TO VALUING PHARMACEUTICAL INVESTMENTS AND FIRMS Cassimon, D
 2001
 4 6 p. 428-
1 p.
 artikel
234 PMI26: ASSESSMENT OF RESPONDENT ACCEPTABILITY OF UTILITY MEASURES: DISCRIMINATORY POWER OF GRAPHIC POSITIONING SCALE VERSUS TRADITIONAL SCALING MEASURES Franic, DM
 2001
 4 6 p. 430-
1 p.
 artikel
235 PMI12: CAREGIVER-BURDEN MEASURES IN ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW Borenstein, J
 2001
 4 6 p. 425-
1 p.
 artikel
236 PMI23: CHANGING STRATEGIES IN THE PROMOTION OF HEALTH CARE RESEARCH IN GERMANY Walshe, R
 2001
 4 6 p. 429-
1 p.
 artikel
237 PMI15: COST ANALYSIS FOR END-OF-LIFE CARE Hanlon, JT
 2001
 4 6 p. 426-
1 p.
 artikel
238 PMI19: COST-EFFECTIVENESS OF TUBERCULOSIS PREVENTIVE THERAPY IN HIV-INFECTED PATIENTS: STUDY OF MISSING VARIABLES Chakrabarti, A
 2001
 4 6 p. 427-428
2 p.
 artikel
239 PMI8: DO HEALTH CARE PURCHASERS PREFER PAYING FOR LIFE EXTENSION OR QUALITY OF LIFE IMPROVEMENT? Kerrigan, J
 2001
 4 6 p. 423-424
2 p.
 artikel
240 PMI6: ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN THREE SETTINGS Annemans, LJ
 2001
 4 6 p. 423-
1 p.
 artikel
241 PMI21: ESTIMATING INFLUENZA-RELATED EXCESS HOSPITAL ADMISSIONS Scuffham, P
 2001
 4 6 p. 428-
1 p.
 artikel
242 PMI27: FACTORS INFLUENCING COMPLETION OF THE EUROQOL EQ-5D GENERIC QOL QUESTIONNAIRE Hazell, ML
 2001
 4 6 p. 430-431
2 p.
 artikel
243 PMI11: FEASIBILITY OF A DATABASE APPROACH TO ADHERENCE WITH OSTEOPOROSIS THERAPY Garfield, FB
 2001
 4 6 p. 425-
1 p.
 artikel
244 PMI3: INCORPORATING CLINICAL LEVEL-OF-EVIDENCE CRITERIA INTO A BREAST CANCER TREATMENT MODEL FOR JAPAN Becker, R
 2001
 4 6 p. 421-422
2 p.
 artikel
245 PMI4: MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO OTHER COUNTRIES—THE TIOTROPIUM EXAMPLE Oostenbrink, JB
 2001
 4 6 p. 422-
1 p.
 artikel
246 PMI22: MICE (MODULE FOR STANDARDISED INDIRECT COST ESTIMATION) INCREASES THE TRANSFERABILITE OF STUDY RESULTS Welte, R
 2001
 4 6 p. 429-
1 p.
 artikel
247 PMI18: MODELING ANTIBIOTIC EFFICACY BY INFECTIOUS AGENT AND PROBABILITY OF RESISTANCE Dombeck, M
 2001
 4 6 p. 427-
1 p.
 artikel
248 PMI7: PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-UTILITY OF ENTACAPONE TREATMENT FOR PARKINSON'S DISEASE Linna, M
 2001
 4 6 p. 423-
1 p.
 artikel
249 PMI24: QUALITY OF LIFE: FUNCTIONING OR NEED FULFILMENT? McKenna, SP
 2001
 4 6 p. 429-430
2 p.
 artikel
250 PMI1: SELF-REPORT OF HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK: BIAS AND THE OPTIMAL RECALL PERIOD Stewart, WF
 2001
 4 6 p. 421-
1 p.
 artikel
251 PMI2: SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS Lenne, X
 2001
 4 6 p. 421-
1 p.
 artikel
252 PMI10: THE ‘NICE’ APPROACH TO PHARMACOECONOMICS: AN ECONOMICS PERSPECTIVE Birch, S
 2001
 4 6 p. 424-425
2 p.
 artikel
253 PMI25: THE RELATION OF DISTRIBUTION-AND ANCHOR-BASED APPROACHES ON INTERPRETATION OF CHANGES IN HEALTH-RELATED QUALITY OF LIFE Norman, GR
 2001
 4 6 p. 430-
1 p.
 artikel
254 PMI14: TO TRANSLATE OR TO ADAPT—WHAT DO THE QUESTIONS MEAN? Doward, LC
 2001
 4 6 p. 426-
1 p.
 artikel
255 PMI9: USE OF AN AUTOMATED PROCESS TO SCAN AND INTERPRET MANUALLY-CODED DATA FORMS IN PHARMACOECONOMICS RESEARCH Reardon, G
 2001
 4 6 p. 424-
1 p.
 artikel
256 PMI16: VALUATION OF INFORMAL CARE van den Berg, B
 2001
 4 6 p. 426-427
2 p.
 artikel
257 PND6: ASSESSING THE COSTS OF PARKINSON'S DISEASE IN GERMANY Spottke, AE
 2001
 4 6 p. 519-520
2 p.
 artikel
258 PND1: ASSOCIATION OF FAMILY HARDINESS WITH WORK PRODUCTIVITY AND ACTIVITY IN FAMILIES OF PEDIATRIC PATIENTS WITH EPILEPSY Meek, PD
 2001
 4 6 p. 517-518
2 p.
 artikel
259 PND2: COMPARISON OF ADVERSE REACTION REPORTS FOR RIVASTIGMINE AND DONEPEZIL USING THE FDA'S ADVERSE EVENT REPORTING SYSTEM Rizzo, J
 2001
 4 6 p. 518-
1 p.
 artikel
260 PND10: CONCOMITANT DRUG USE IMPLICATIONS IN ALZEIMER'S DISEASE PATIENTS USING DONEPEZIL Jackson, A
 2001
 4 6 p. 521-
1 p.
 artikel
261 PND3: COST-EFFECTIVENESS OF DEEP BRAIN STIMULATION IN PATIENTS WITH PARKINSON'S DISEASE Dodel, RC
 2001
 4 6 p. 518-519
2 p.
 artikel
262 PND15: COST-EFFECTIVENESS OF THERAPY FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): INTRODUCING AN ECONOMIC MODEL FOR COPAXONE (GLATIRAMER ACETATE) Bose, UK
 2001
 4 6 p. 523-
1 p.
 artikel
263 PND11: DISEASE MANAGEMENT IN MIGRAINE AND TENSION-TYPE HEADACHE — RESULTS OF A SOCIO-ECONOMIC PILOT STUDY Schipp, B
 2001
 4 6 p. 521-
1 p.
 artikel
264 PND7: ESTIMATION OF THE COSTS OF MULTIPLE SCLEROSIS BASED ON 157 FRENCH PATIENTS Marissal, JP
 2001
 4 6 p. 520-
1 p.
 artikel
265 PND9: IMPACT OF RIVASTIGMINE ON ANTIPSYCHOTIC UTILIZATION AND COST IN ALZHEIMER'S DISEASE Mends, P
 2001
 4 6 p. 520-521
2 p.
 artikel
266 PND8: IMPLICATIONS OF PRESCRIBING FOR PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS): INTRODUCING A TREATMENT ALGORITHM FOR GLATIRAMER ACETATE (COPAXONE) Brambleby, P
 2001
 4 6 p. 520-
1 p.
 artikel
267 PND14: QUALITY OF LIFE OF WOMEN SUFFERING FROM MENSTRUAL MIGRAINE AND RELATIONSHIP WITH MOOD Arpinelli, F
 2001
 4 6 p. 522-523
2 p.
 artikel
268 PND5: THE COST OF SECONDARY STROKE IN POLAND Niewada, MP
 2001
 4 6 p. 519-
1 p.
 artikel
269 PND4: THE IMPACT OF DRUG INTERACTIONS ON HOSPITALIZATION RATES FOR ALZHEIMER'S PATIENTS TREATED WITH DONEPEZIL Rizzo, J
 2001
 4 6 p. 519-
1 p.
 artikel
270 PND12: TREATMENT AND HEALTH-CARE SATISFACTION AMONG PEOPLE WITH MIGRAINE HEADACHES Mackell, JA
 2001
 4 6 p. 522-
1 p.
 artikel
271 PND13: TREATMENT AND QUALITY OF LIFE AMONG PEOPLE WITH MIGRAINES Mackell, JA
 2001
 4 6 p. 522-
1 p.
 artikel
272 POD9: AN ANALYSIS OF THE USEFULNESS AND TRANSPARENCY OF COST-EFFECTIVENESS LITERATURE FOR SURGICAL DEVICES AND PROCEDURES Basskin, LE
 2001
 4 6 p. 469-470
2 p.
 artikel
273 POD13: A RISK-ASSESSMENT MODEL FOR ERECTILE DYSFUNCTION: THE SEXUAL-HEALTH INVENTORY FOR MEN AND RELATED MEDICAL CONDITIONS Ambegaonkar, AJ
 2001
 4 6 p. 471-
1 p.
 artikel
274 POD11: BENIGN PROSTATIC HYPERPLASIA—CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE: RISK OF SOMNOLENCE Perrin, P
 2001
 4 6 p. 470-
1 p.
 artikel
275 POD12: BENIGN PROSTATIC HYPERPLASIA: RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE Levy, E
 2001
 4 6 p. 470-471
2 p.
 artikel
276 POD4: COST-CONSEQUENCES OF ORTHOPAEDIC SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS Green, C
 2001
 4 6 p. 467-468
2 p.
 artikel
277 POD14: COST-EFFECTIVENESS ANALYSIS OF THE SPECTRON VERSUS CHARNLEY HIP PROSTHESES Briggs, AH
 2001
 4 6 p. 471-
1 p.
 artikel
278 POD6: ECONOMIC EVALUATION OF TREATING ERECTILE DYSFUNCTION IN SPAIN: THE PRIMARY CARE APPROACH VERSUS SPECIALIZED CARE Domìnguez-Gil, A
 2001
 4 6 p. 468-
1 p.
 artikel
279 POD1: ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE Payne, K
 2001
 4 6 p. 466-
1 p.
 artikel
280 POD10: THE BPE-PIT—AN ADAPTATION OF THE BPE-P FOR USE IN A MULTINATIONAL CLINICAL TRIAL Eremenco, SL
 2001
 4 6 p. 470-
1 p.
 artikel
281 POD5: THE COST EFFECTIVENESS OF AN EXTRACORPOREAL LIVER ASSIST DEVICE FOR PATIENTS WITH FULMINANT HEPATIC FAILURE Sullivan, EM
 2001
 4 6 p. 468-
1 p.
 artikel
282 POD7: THE EF-VAS: A PREFERENCE-BASED SELFADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT Torrance, G
 2001
 4 6 p. 468-469
2 p.
 artikel
283 POD3: THE PSYCHOMETRIC TESTING OF THE HUNGARIAN VERSION OF THE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE Lovas, K
 2001
 4 6 p. 467-
1 p.
 artikel
284 POD2: USING CONTINGENT VALUATION IN A RCT FOR INDUCTION AND MAINTENANCE OF ANAESTHETIC AGENTS FOR DAY-CASE SURGERY Elliott, RA
 2001
 4 6 p. 466-467
2 p.
 artikel
285 POD8: VALIDATION OF VAGINAL CONTRACEPTION ACCEPTABILITY QUESTIONNAIRE Novak, A
 2001
 4 6 p. 469-
1 p.
 artikel
286 PRP1: A COMPARISON OF SIX PHONE INTERVIEWS DESIGNED TO MEASURE HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK Ricci, J
 2001
 4 6 p. 460-461
2 p.
 artikel
287 PRP6: ASMACARE STUDY. ASSESSMENT OF THE IMPACT OF AN INTERVENTION DESIGNED TO IMPROVE THE MANAGEMENT OF ASTHMA PATIENTS Espinosa, C
 2001
 4 6 p. 462-463
2 p.
 artikel
288 PRP14: ASSESSING PATIENTS' PREFERENCES FOR CONVENTIONAL AND HOMEOPATHIC TREATMENT FOR ASTHMA—A CONJOINT ANALYSIS STUDY Ratcliffe, J
 2001
 4 6 p. 466-
1 p.
 artikel
289 PRP12: ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS Meszaros, A
 2001
 4 6 p. 465-
1 p.
 artikel
290 PRP2 ASTHMA MANAGEMENT AND OUTCOMES IN ITALY Arpinelli, F
 2001
 4 6 p. 461-
1 p.
 artikel
291 PRP4: COST-CONSEQUENCE ANALYSIS OF TIOTROPIUM VERSUS IPRATROPIUM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) Mölken, Rutten-van
 2001
 4 6 p. 461-462
2 p.
 artikel
292 PRP7: COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL TREATMENT WITH ALMITRINE BISMESYLATE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Gorecka, D
 2001
 4 6 p. 463-
1 p.
 artikel
293 PRP9: COST-OF-ILLNESS STUDY OF PATIENTS WITH ALLERGIC ASTHMA AND SEASONAL ALLERGIC RHINITIS IN GERMANY Quednau, K
 2001
 4 6 p. 464-
1 p.
 artikel
294 PRP11: EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA Greiner, W
 2001
 4 6 p. 464-465
2 p.
 artikel
295 PRP5: ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR) Ricci, J
 2001
 4 6 p. 462-
1 p.
 artikel
296 PRP13: IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE Duprat-Lomon, I
 2001
 4 6 p. 465-
1 p.
 artikel
297 PRP8: LIFETIME COSTS OF COPD IN THE NETHERLANDS Feenstra, T
 2001
 4 6 p. 463-
1 p.
 artikel
298 PRP3: SPECIFIC IMMUNOTROPIC THERAPY — ASPECTS OF COST-EFFECTIVENESS Prosekova, E
 2001
 4 6 p. 461-
1 p.
 artikel
299 PRP10: VARIATIONS IN COVERAGE FOR EFFECTIVE SERVICES FOR ASTHMA: IMPACT OF NATIONAL GUIDELINES Hanlon, JT
 2001
 4 6 p. 464-
1 p.
 artikel
300 QL1: CAN HEALTH STATE VALUES BE PREDICTED FROM HEALTH-RELATED QUALITY OF LIFE MEASURES? Svensson, K
 2001
 4 6 p. 414-
1 p.
 artikel
301 QL2: ESTIMATING PATIENTS' PREFERENCES IN TREATMENT CHOICES INVOLVING RISK: A NEW MODIFIED STANDARD GAMBLE METHOD Walshe, R
 2001
 4 6 p. 414-415
2 p.
 artikel
302 QL3: PSYCHOMETRIC PERFORMANCE OF THE MEDICAL OUTCOMES STUDY SLEEP SCALE IN THE US GENERAL POPULATION Hays, RD
 2001
 4 6 p. 415-
1 p.
 artikel
303 RP1: DOES ILLNESS-RELATED LOST PRODUCTIVE WORK TIME VARY BY JOB DEMAND OR JOB CONTROL: A CASE STUDY OF ALLERGIC RHINITIS (AR) Stewart, WF
 2001
 4 6 p. 419-
1 p.
 artikel
304 RP3: PREPARING THE ASTHMA SYMPTOM UTILITY INDEX FOR INTERNATIONAL USE: TRANSLATION AND LINGUISTIC VALIDATION Flood, EM
 2001
 4 6 p. 419-420
2 p.
 artikel
305 RP2: THE NET COST OF ASTHMA TO A US PUBLIC MEDICAID PROGRAM Pannicker, S
 2001
 4 6 p. 419-
1 p.
 artikel
                             305 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland